These results clearly demonstrate that the anti-inflammatory properties of hESC-MSC-IMRC-CM and hESC-MSC-IMRCs are critical for their therapeutic effects in the treatment of PF in mice at both stages of early development and late progression of the disease, which is in part through the mechanism of regulating the Tlr4/MyD88 signaling pathway. This evidence concerns the gene TLR4 and pemphigus foliaceus.